Gynazol 2% (Butoconazole nitrate 2% vaginal cream) is commonly used for therapeutic support across key symptomatic and infective domains associated with localized fungal overgrowth. Its use is aligned with the therapeutic goal of addressing fungal overgrowth.

Therapeutic Focus and Relief

This medication is primarily relevant in conditions characterized by periods of heightened symptoms associated with Vulvovaginal Candidiasis (VVC), which typically involves susceptible Candida species. It is applied in conditions with disruptive symptom manifestations to help address the fungal overgrowth and supports the process of symptomatic relief in these conditions.

Gynazol 2% is commonly used to help manage symptoms related to acute episodes, including vaginal and vulvar itching, burning sensation, and abnormal discharge. The treatment may assist with symptomatic relief of these core symptoms and is relevant for easing symptoms related to inflammatory or irritative states, such as soreness and redness.

“The treatment supports the patient during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.”

The cream is commonly used across conditions presenting with acute episodes, including symptom patterns ranging from mild-to-moderate to, when clinically relevant, more intense manifestations of local irritation. It offers symptomatic relief that helps patients cope more steadily with difficult acute or recurrent episodes, and supports general well-being during symptomatic phases, which may assist with maintaining functional stability.

---

Quick Fact: Relief for Localized Discomfort

Gynazol 2% is relevant when supportive symptom management is appropriate, helping to ease the overall burden of symptoms associated with VVC.

Regulatory References

1. NIH DailyMed drug label

Population Eligibility Status

Gynazol 2% is authorized for use primarily in non-pregnant adult women who require treatment for vulvovaginal candidiasis. The official regulatory labeling strictly defines who must not use the medicine and which populations require conditional use.

Contraindications (Absolute Non-Eligibility)

The medicine is contraindicated for any individual with a documented history of hypersensitivity or allergy to Butoconazole nitrate or to any other component found within the cream formulation. This exclusion is absolute.

Age-Related and Conditional Eligibility

• Pediatric Use: Safety and effectiveness have not been established in children, meaning this population is excluded from use according to regulatory documentation.
• Adult and Geriatric Use: Use is established and documented for these populations.
• Pregnancy: The cream is classified as requiring conditional use. It should be administered only when the potential benefit is judged to outweigh the potential risk to the fetus.
• Lactation: Caution must be exercised when administering to a nursing mother, as it is officially unknown whether the drug is excreted into human milk.
• Recurrent Infections: Use is restricted in cases of recurrent or frequent infections; these patients must undergo clinical assessment to rule out potential underlying serious conditions, such as HIV or diabetes.

Interactions with other medicines and products

Property	Description
Medicinal product categories with documented interactions	None documented.
Specific interacting medicines (if explicitly listed)	None documented.
Product classes or substance categories identified in official documents	Latex or rubber products (non-medicinal devices)
Mechanistic basis of interactions (only if stated in label)	Physical incompatibility where an excipient (mineral oil) is documented to weaken latex or rubber materials.
Timing-based interaction rules (if applicable)	Use of latex or rubber barrier products is not recommended within 72 hours following treatment.

---

Interaction Classifications

Property	Description
Interaction severity classification (as defined in official documents)	Device Failure Risk.
Regulatory basis (EMA / FDA / etc.)	Official Government Drug Monograph.

---

Official Interaction Statements

Regulatory labeling confirms that no clinically significant systemic drug-drug interactions are expected with this product. This assessment is based on the minimal systemic absorption of the active ingredient, Butoconazole, which results in negligible plasma concentrations. Consequently, no warnings are required for metabolic, transporter, or exposure-modifying drug combinations.

The single documented constraint relates to a physical incompatibility between the cream formulation and non-medicinal devices. The cream contains an excipient, mineral oil, which is officially stated to weaken the integrity of products made from latex or rubber, specifically including condoms and vaginal contraceptive diaphragms.

Due to this documented risk of material weakening and potential device failure, the official prescribing information mandates a timing-based restriction: the use of such latex or rubber barrier products is not recommended within 72 hours after the cream is administered. No interactions are formally documented with food, alcohol, or herbal products.

Molecular Target and Pathway Inhibition

The mechanism of Butoconazole (Gynazol 2%) is initiated by its selective action as an inhibitor of the fungal enzyme lanosterol 14-alpha demethylase (CYP51). This enzyme is critical for the ergosterol biosynthesis pathway. Butoconazole binds to the enzyme's heme iron, halting the conversion of lanosterol precursors into ergosterol, the primary steroid component of the fungal cell membrane.

Intracellular Consequence and Destruction

The resulting ergosterol depletion and the concurrent accumulation of structurally toxic methylated sterol precursors destabilize the fungal cell membrane. This molecular defect compromises the membrane's structural integrity and increases its permeability. This profound cellular damage leads to the loss of essential intracellular contents and creates conditions that promote cell lysis and the destruction of the fungal cell.

Mechanistic Selectivity

The mechanism exhibits selectivity by targeting the ergosterol pathway, which is distinct from the cholesterol pathway utilized by human cells, focusing the inhibitory action on the fungal organism.

How to Use Gynazol 2%

The use of Gynazol 2% (butoconazole nitrate 2% vaginal cream) is based on a standardized, single-dose administration protocol. This medicine is strictly for intravaginal use only and must not be administered orally or used on other topical areas.

Official Dosing and Administration

The standard regimen for non-pregnant women is defined as a single application of one full applicatorful of the 2% cream, typically administered at bedtime. This standardized dose is approximately 5 grams of the cream, which delivers an intended dose of 100 mg of the active ingredient, butoconazole nitrate. The cream is supplied in a prefilled, disposable applicator that should be used for the application and discarded afterward to ensure the correct measured dose is delivered.

Population-Specific Use

While the standard regimen is a single dose, an alternate 6-day regimen is documented for use in pregnant women during the second and third trimesters, which must be carried out under the supervision of a physician. The drug is stated to be safe and effective for use in non-pregnant women, but its safety and efficacy have not been established for use in pediatric patients (under 18 years of age).

Evidence for Local Treatment of Vulvovaginal Candidiasis (VVC)

Research for this product was studied for the local treatment of Vulvovaginal Candidiasis (VVC), a condition involving periods of heightened symptoms caused by Candida species. The primary research approach involved Randomized Controlled Trials (RCTs). These trial designs were evaluated in studies comparing the product against a non-medicated vehicle or other established topical agents. These studies typically included adult, non-pregnant female subjects who presented with symptoms and a confirmed laboratory presence of the fungus. Research examined how symptoms change over time, and how those changes were measured during the study period.

The main focus of the clinical research was evaluated in settings exploring temporary physiological imbalance linked to the fungal presence. Studies monitored two main outcomes: Clinical Cure, which focused on the assessment of outcomes related to physical discomfort such as irritation and burning, and Mycological Eradication, which used laboratory tests to check for the absence of the fungus. Findings describe patterns observed in the studies over the short-term treatment intervals.

---

Study Focus: Therapeutic Cure and Symptom Resolution

The key measurement in many trials was observed in the outcome of Therapeutic Cure, which is a combined assessment. This measure simultaneously tracks the assessment of outcomes capturing phases of heightened symptom activity and the laboratory confirmation of Mycological Eradication. When researchers analyzed the data, studies report how symptoms evolved in the observed populations when compared to the study’s comparators.

---

Long-Term Studies and Follow-up

The research conducted typically involved follow-up durations that were limited to short periods after treatment completion, often extending only up to 30 days. Consequently, long-term effects are not fully established. The existing evidence base primarily addresses the short-term assessment of symptoms and the immediate clearance of the fungus. There is limited information for long-term outcomes that may describe the possibility of recurrence or the durability of the initial assessment months or years later.

---

Evidence in Special Populations

The main clinical research was evaluated in the specific population of adult, non-pregnant women with laboratory-confirmed VVC. Therefore, the results apply only to the populations studied. Data for certain groups remain limited. For instance, few specific studies have monitored the effects and measured outcomes in pregnant women, and the evidence for that population remains limited.

Common questions about Gynazol 2% (FAQ)

---

Q: What is the primary active ingredient in Gynazol 2%?

Gynazol 2% contains Butoconazole Nitrate as its primary active ingredient. According to the official product information, this is an antifungal medication indicated for the treatment of vulvovaginal candidiasis, commonly referred to as a yeast infection.

---

Q: Does Gynazol 2% require a prescription from a healthcare professional?

Regulatory documents indicate that Gynazol 2% is classified as a prescription-only medicine. This means that access to the medication generally requires authorization from a licensed healthcare provider.

---

Q: What kind of infections is Gynazol 2% used to treat?

Official information indicates that Gynazol 2% is specifically indicated for the local treatment of vulvovaginal candidiasis (VVC). This condition is a fungal infection of the vagina and surrounding tissues caused by susceptible Candida species.

---

Q: What is the typical method of administration for Gynazol 2%?

According to the official product information, Gynazol 2% is intended to be administered as a single vaginal dose application. The product is formulated as a cream supplied in a pre-filled vaginal applicator.

---

Q: Is Gynazol 2% safe to use during the first trimester of pregnancy?

Official regulatory documents advise that Gynazol 2% should only be used during the first trimester of pregnancy when clearly needed. This is generally when the potential benefits of treatment are deemed to outweigh the potential risks to the developing fetus, and the decision is made after careful consideration by the prescribing healthcare professional.

---

Q: Can Gynazol 2% be used while breastfeeding?

Studies and official product information state that it is not known whether Butoconazole Nitrate is excreted into human milk. Because many medicines can be transferred this way, Gynazol 2% should be used with caution, and its use during breastfeeding should be considered under the guidance of a healthcare professional.

---

Q: How should Gynazol 2% be stored?

Regulatory documents state that Gynazol 2% should be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). The regulatory documents advise against freezing the product to maintain its quality and integrity.

---

Q: What is the appearance of the Gynazol 2% product?

According to the official product information, Gynazol 2% is a white cream. This cream, which contains the active ingredient Butoconazole Nitrate, is supplied in a single-dose vaginal applicator.

How to Store and Dispose of Gynazol 2%?

Gynazol 2% vaginal cream must be stored under specific environmental and temperature conditions as defined in regulatory labeling.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Controlled Room Temperature: 25 C (77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F).
Prohibited Conditions	Do not freeze. Avoid heat above 30 C and excess moisture.
Container Rule	Keep the medicine in its original container and keep the container tightly closed.
Child Safety	Store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Gynazol 2% must be disposed of safely according to official guidelines. The preferred method is a community drug take-back program. If unavailable, mix the medicine with an undesirable substance, seal it in a bag, and discard it in the household trash. Do not flush the medication down the toilet or pour it into a drain.